ATOS:NSD-Atossa Therapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 2.72

Change

0.00 (0.00)%

Market Cap

USD 0.19B

Volume

0.01B

Average Target Price

USD 7.00 (+157.35%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Atossa Therapeutics, Inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the United States. The company's lead program is the development of Endoxifen, an active metabolite of tamoxifen which is in Phase II studies to treat and prevent breast cancer. It is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and Chimeric Antigen Receptor T-cell therapies, directly to the site of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2009 and is headquartered in Seattle, Washington. Address: 107 Spring Street, Seattle, WA, United States, 98104

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-02-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

N/A

USD61.26B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD55.25B 20.66 14.64
REGN Regeneron Pharmaceuticals, Inc

N/A

USD48.27B 14.76 12.06
ALXN Alexion Pharmaceuticals, Inc

N/A

USD33.58B 56.16 33.22
BGNE BeiGene, Ltd

N/A

USD29.06B N/A N/A
RPRX Royalty Pharma plc

N/A

USD28.27B 22.60 14.17
SGEN Seagen Inc

N/A

USD27.38B 44.84 41.48
BNTX BioNTech SE

N/A

USD26.25B -99,999.99 N/A
GMAB Genmab A/S

N/A

USD22.15B 26.59 3.17
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ATOS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 186.32% 99% A+ 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 186.32% 99% A+ 98% A+
Trailing 12 Months  
Capital Gain 124.79% 77% C+ 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 124.79% 77% C+ 83% B
Trailing 5 Years  
Capital Gain -96.36% 8% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -96.36% 8% F 2% F
Average Annual (5 Year Horizon)  
Capital Gain -32.09% 7% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -32.09% 6% F 3% F
Risk Return Profile  
Volatility (Standard Deviation) 51.19% 55% F 27% F
Risk Adjusted Return -62.69% 13% F 8% F
Market Capitalization 0.19B 31% F 32% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 26.39 9% F 7% F
Price / Cash Flow Ratio -21.33 73% C 81% B-
EV/EBITDA 0.09 74% C 96% A
Management Effectiveness  
Return on Equity -104.16% 28% F 11% F
Return on Invested Capital -157.24% 12% F 5% F
Return on Assets -57.96% 11% F 4% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.13 91% A- 89% B+
Short Percent 8.06% 37% F 24% F
Beta 2.13 20% F 12% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.